Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $7

Moomoo NewsFeb 20 08:31 ET · Ratings

Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Blueprint Medicines (BPMC)

TipRanksFeb 20 08:10 ET · Ratings

Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $11

Moomoo NewsFeb 19 08:31 ET · Ratings

Market-Moving News for February 19th

BenzingaFeb 19 07:23 ET

Express News | Chemomab Therapeutics Shares Are Trading Higher After the Company Announced the Completion of Its End-of-phase 2 FDA Meeting and Alignment on a Single Phase 3 Registration Study for Nebokitug

BenzingaFeb 19 07:17 ET

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns With FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

GlobeNewswireFeb 19 07:00 ET